Abstract: Gadolinium-based carbon nanostructures are poised to make a significant impact as advanced contrast agents (CAs) for magnetic resonance imaging (MRI) in medicine. This paper reviews and forecasts gadonanotubes as synthons for the design of high-performance MRI CA probes with efficacies up to 100 times greater than current clinical CAs. This level of performance is vital for achieving the goal of cellular and molecular imaging with MRI. These new materials will be useful for in vivo MRI applications as circulating drug nanocapsules because of their low toxicities, extremely high relaxivities, and potential for cellular targeting and induced cell death by magnetic hyperthermia.
Introduction
Magnetic resonance imaging (MRI) is one of the most powerful and central techniques in diagnostic medicine and biomedical research (Mansfield 2004) . Primarily, MRI non-invasively produces anatomical details for improved diagnosis of many diseases. Secondly, MRI also provides valuable information about the physiochemical state of tissues and blood flow. Thus, MRI is the method of choice for the diagnosis of many types of injuries and conditions, and it is not surprising that the use of MRI scanners is growing at an explosive rate. Today more than 22 000 MRI systems operate worldwide.
In clinical MRI, the nuclear magnetic resonance signal from water protons in living tissue are used to image organs and disease sites, such as tumors, in 3D. The intensity of this MR signal depends on three important intrinsic tissue factors: the proton density, the longitudinal relaxation time, T 1 , and the transverse relaxation time, T 2 . Thus, various mathematical techniques have been developed to highlight the differences in T 1 or T 2 to obtain good contrast, ie, the difference in appearance of different tissues in an MR image. Otherwise, MR images would be fairly featureless since the amount of water does not vary significantly in the various tissues of in the body.
The development of MRI has also concurrently led to the development of chemical contrast-enhancement products called contrast agents (CAs). MRI CAs are used primarily to improve disease detection by increasing sensitivity and diagnostic confidence. There are several types of MRI CAs including extracellular fluid space (ECF) agents, extended-residence-intravascular agents (blood pool), and tissue (organ)-specific agents. Nearly all commercial CAs available today are ECF agents that distribute extracellularly and excrete exclusively via the kidney. Annually, approximately 60 million MRI procedures are performed worldwide; 30-35% of these procedures use MRI CAs.
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CAs used in clinical MRI procedures operate by changing the proton nuclear spin relaxation times of water molecules in their vicinity, enhancing the detected MR signal in tissue (Lauffer 1987; Caravan et al 1999; Merbach et al 2001; Krause and Editors 2002) . Thus, the most commonly used clinical CAs decrease T 1 relaxation times (also referred to as spin-lattice relaxation ) of water protons in living tissue in the vicinity of the paramagnetic CA. All CAs are paramagnetic (with unpaired electrons) because paramagnetic CAs generate very large lattice fields (magnetic and nuclear environments with which the protons interact during T 1 relaxation) in the immediate neighborhood of the CA, which greatly shorten the T 1 of any water molecule that approaches the paramagnetic center. The term "relaxivity" (r 1 for T 1 relaxation) is the key determinant for evaluating the efficacy of any MRI CA. It is defined as the change in the relaxation rate of the water protons per molar concentration of the paramagnetic CA, and is expressed in units of mM -1 sec chelates are distributed extracellularly, with a low retention time in the blood pool (about 60 seconds), which makes them unsuitable for MRA. In addition, MRI of individual cells and their tissues (MR molecular imaging) requires that each Gd 3+ center possess an extremely large relaxivity in order to induce sufficient signal intensity. This requirement is due to the fact that the concentration of Gd 3+ centers that can be delivered or attached to the surface of a specific cell is largely limited to the nanomolar (nM) range by biological constraints (Nunn et al 1997) . Gadolinium CAs in current clinical use with r 1 ~4 mM -1 s -1 do not possess sufficiently large relaxivities for molecular imaging since r 1 values greater than 100 mM -1 s -1 are generally required (Nunn et al 1997) .
Gadonanotubes
Gd 3+ -based carbon nanotube structures with their unique nanoscalar properties and superior performance as MRI CAs show promise for molecular imaging and other advanced applications.
Single-walled carbon nanotubes (SWNTs) possess unique characteristics that make them desirable for biomedical applications (Martin and Kohli 2003) . The ideal length for medical applications is uncertain, but ultra-short nanotubes (20-100 nm) or US-tubes (Gu et al 2002; Mackeyev et al 2005) are probably best suited for cellular uptake, biocompatibility, and eventual elimination from the body. Additionally, the US-tube exterior surface provides a versatile scaffold for attachment of chemical groups for solubilizing or targeting purposes, while its interior space allows for encapsulation of atoms, ions, and even small molecules (Suenaga et al 2000; Monthioux 2002; Mackeyev et al 2005) whose cytotoxicity may be sequestered within the short carbon nanotube. Finally, medical-imaging agents derived from US-tubes hold promise for intracellular imaging, since carbon nanotubes have been shown to translocate into the interior of cells with minimal cytotoxicity (Dugan et al 1997; Wang et al 1999; Kam et al 2004; Lu et al 2004; Pantarotto et al 2004) .
Recently, the first carbon nanotube-based CA called a "gadonanotube" (Figure 1 inset) was reported (Sitharaman et al 2005) . This CA harnessed the ability of ultra-short singlewalled carbon nanotubes (US-tubes) to encase smaller ions or molecules within their framework by successfully loading and confining aquated Gd Nuclear magnetic relaxation dispersion (NMRD) profiles can be of great help in determining the parameters influencing relaxivity, and they have played an important role in the development of our understanding of proton relaxivity. NMRD profiles are proton-spin relaxivities measured as a function of magnetic field. The NMRD profile (B = 5 × 10 -4 -9.4 T)
for an aqueous solution of a Gd 3+ n @US-tube sample in 1% SDBS (sodium dodecylbenzene sulfonate, a surfactant employed to suspend the highly lipophilic SWNTs in water) solution at 37°C, is presented in Figure 1 . Also presented, for comparative purposes, are data for one of the commercially available MRI CAs, [Gd(DTPA)(
). For any magnetic field in Figure 1 , the relaxivity for the Gd In addition to the exceptionally large relaxivity values obtained for the gadonanotubes, the shape of the NMRD curve, as shown in Figure 1 , is also considerably different from that reported so far for any other Gd 3+ -based system. In particular, the relaxivities are continuously decreasing with increasing magnetic field at proton Larmor frequencies below 1 MHz, in contrast to the usual Gd 3+ CAs which present constant values at these low fields. Even more remarkable is the finding that at high magnetic fields (>60 MHz), the relaxivities remain practically constant, whereas a strong decrease is observed for the usual Gd 3+ CAs.
The Solomon-Bloembergen-Morgan theory is unable to predict the observed shape of the NMRD profile and thus does not appear appropriate for gadonanotubes. Clearly, further investigations are needed in order to explain both the extremely large relaxivities and the magnetic-field dependency of the proton relaxivities for the gadonanotubes and possibly also other nanoscalar MRI CA materials. However, the data can be used to evaluate their potential efficacy as advanced MRI CAs.
To this end, we also recently conducted T 1 -weighted MRI phantom studies of the gadonanotubes at a 0.04 mM (Gd 3+ ). Additional vials containing the commercial contrast agent Magnevist TM and deionized water solutions were also included in the imaging section as a reference for comparative purposes.
Representative T 1 -weighted MRI images of the vials are shown in Figure 2 . At 0.04 mM (Gd 3+ ) the gadonanotubes showed extremely large signal enhancement compared to Magnevist TM (ca. 100 times!) at the same concentration (Figures 2 and 3) . especially benefit microtesla MRI imaging technologies (McDermott et al 2004) . At high magnetic fields (>60 MHz), the ability of the gadonanotubes to maintain a nearly constant relaxivity is particularly important (Mansfield 2004) given the current tendency to develop MRI scanners of higher and higher fields; at these same fields, the contrast-enhancing effect of traditional CAs drops off. Currently, the most efficient T 1 agents show a typical high-field relaxivity peak centered around 30-40 MHz which is characteristic of slow molecular rotation which can give maximum relaxivities of 40-50 Mm -1 s -1 . Above this frequency, the relaxivity quickly vanishes to very small values for current MRI CAs.
Future applications Universal Mr probes
In this respect, gadonanotubes may represent a significant breakthrough in CA design for high-field imaging.
Cellular-and molecular-imaging probes
Molecular imaging is a new frontier for diagnostic medicine. It aims to strengthen diagnostic accuracy of existing image modalities and their interpretation by probing unique biological signatures or sub-cellular processes that are at the cause of disease. The gadonanotube materials considered here would seem to hold exceptional promise for molecular imaging for the following reasons: a) Their external surfaces can be used as a scaffold to attach a wide variety of agents. These agents can be watersolubilizing groups, biocompatible coverings, and even antibodies or peptides for active targeting of a specific cell type of interest, such as malignant cells. b) Biological constraints limit targeted receptor sites on cell surfaces to very low concentrations (nM-pM/g of tissue) (Nunn et al 1997) . The exceptionally large T 1 relaxivities of the gadonanotubes (Figure 1 ) could provide sufficient signalto-noise to image cell-surface receptor sites in the nanomolar range. For example, for a clinical CA with r 1 = 4.0 mM -1 s -1 at clinical field strengths, the minimum detectable concentration of Gd 3+ is 10 -4 M (Nunn et al 1997) . The increase in relaxivity provided by the gadonanotube changes this minimum concentration to approximately 2 x 10 -9 M. c) Recently, SWNTs have been shown to translocate into the interior of cells with minimal cytotoxicity (Dugan et al 1997; Wang et al 1999; Kam et al 2004; Lu et al 2004; Pantarotto et al 2004 
Guided-therapy probes
The superparamagnetic gadonanotubes also show promise for the development of the first Gd 3+ -based MRI image-guided therapeutic agent that can used for targeted magnetic-fieldinduced hyperthermia. While heating a cancer cell or tumor to the point of therapeutic destruction can be accomplished by several methods (Moroz et al 2002) , the least intrusive is the use of a magnetically mediated agent. Although any magnetic material can be magnetically induced to generate heat, single domain particles (superparamagnetic materials like the gadonanotubes) are preferred because they can produce far more heat at safer (lower) magnetic fields compared with ferromagnetic materials (Moroz et al 2002) . The limitation of hyperthermia for human treatment is the failure to generate appreciable heat at safe magnetic fields. However, recent results with ultra-small iron oxide particles (USPIOs) have shown promise for the first human trials (Moroz et al 2002) . The gadonanotubes may make ideal MRI-delivery capsules for cancer imaging-therapy by magnetic hyperthermia due to their nanoscalar size, superparamagnetism, external derivatization potential, and intrinsically intracellular nature. Furthermore, non-spherical particles such as the gadonanotubes are yet to tested as hyperthermia agents, and it is possible that their unique rod-shaped geometry (aspect ratio of 100:1) may augment performance through non-axial Brownian relaxation (Rosensweig 2002) .
